Gen İlaç Signs 5-Year Exclusive Distribution Agreement with Pfizer

Gen İlaç has entered into a strategic partnership with global pharmaceutical giant Pfizer. Under the agreement, Gen İlaç will undertake the exclusive distribution of certain Pfizer products in Turkey. The term of the agreement is set at 5 years. This partnership aims to strengthen Gen İlaç's position in the Turkish pharmaceutical market. By taking over the local distribution of Pfizer's extensive product portfolio, Gen İlaç will expand its reach in the healthcare sector. Financial details of the agreement have not yet been disclosed to the public. The collaboration is expected to create significant synergies for both companies. While Gen İlaç will benefit from Pfizer's R&D capabilities and global experience, Pfizer will gain a more effective distribution network in the Turkish market. The agreement is anticipated to increase competition in the pharmaceutical sector and facilitate patient access. This is not investment advice.

📊 PFE — Piyasa Yorumu

▲ up · 60%

The news is a positive development for Pfizer, potentially boosting revenue by expanding its distribution network. However, technical indicators are weak: RSI at 31.7 is near oversold territory, MACD is below the signal line, and the price is below both the 20-day and 50-day moving averages. A 2.5% decline in the last 24 hours reflects short-term pressure. While the news is positive, the technical picture may take time to recover, so upside movement could be limited.

RSI 14

31.7

MACD

-0.18

24h Δ

-2.49%

Canlı Grafikler